Biomarker Analysis for Traumatic Brain Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to predict recovery timelines for individuals with mild traumatic brain injury (mTBI) by analyzing blood samples and using eye-tracking technology (Combination iSTAT/Alinity and IR Oculography). The study examines how specific blood markers and eye movements can enhance doctors' understanding of recovery. Individuals who have recently suffered a mild head injury (within the last 24 hours) and can communicate in English may be suitable for this trial. As an unphased study, it offers participants the chance to contribute to groundbreaking research that could improve recovery predictions for future patients.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this protocol is safe for use in traumatic brain injury recovery prediction?
Research has shown that using the iSTAT/Alinity and IR Oculography together can help predict recovery after a traumatic brain injury. The i-STAT TBI cartridge delivers fast, accurate results for assessing mild brain injuries, making the technology reliable and safe. While specific reports of side effects are absent, these tools aim to reduce the need for CT scans, thereby lowering radiation exposure. This emphasis on safety and efficiency suggests that the treatment is well-tolerated.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores innovative ways to diagnose traumatic brain injury (TBI) using biomarker analysis. Unlike current methods that often rely on imaging techniques like CT scans, this approach uses blood biomarkers and eye movement tracking to detect signs of TBI. This could potentially allow for quicker and more precise diagnosis, helping to guide treatment decisions more effectively. By focusing on biological markers, this method might offer a more detailed understanding of the injury's impact, leading to better outcomes for patients.
What evidence suggests that this combination of blood biomarkers and eye tracking is effective for predicting recovery timelines after traumatic brain injury?
This trial will evaluate the effectiveness of combining the Alinity i TBI test and the i-STAT TBI plasma test with IR Oculography for traumatic brain injury (TBI) assessment. Studies have shown that the Alinity i TBI test effectively detects signs of TBI in the blood, with a sensitivity of 96.7%. The i-STAT TBI plasma test quickly and accurately checks for mild TBI. Eye tracking, or IR Oculography, can help predict recovery outcomes by monitoring eye movements. Together, these tools could lead to faster diagnoses and reduce the need for CT scans, which use radiation. These promising methods aim to provide a more complete understanding of TBI and the recovery process.12346
Who Is on the Research Team?
James Buskirk, PT, DPT, PhD, MS
Principal Investigator
Captain James A. Lovell Federal Health Care Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Use of blood biomarkers and video IR oculography to assess the necessity of head CT scan and predict recovery timeline
Follow-up
Participants are monitored for safety and effectiveness after assessment
What Are the Treatments Tested in This Trial?
Interventions
- Combination iSTAT/Alinity and IR Oculography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Captain James A. Lovell Federal Health Care Center
Lead Sponsor